Prof. Lee P. Shulman

Northwestern University, USA

Email: [email protected]

Qualifications

1983 Ph.D., Cornell University Medical College, USA

1979 B.Sc., Cornell University, USA

Publications (selected)

1. Salhia, B., Roman, L., Guo, X. M., et al. (2026). OvaPrint, a liquid biopsy for adnexal mass evaluation, shows superior specificity for benign tumors and selective detection of high-grade serous ovarian cancer. Gynecologic Oncology, 208(Suppl S), S392–S393.
2. Leigh, D., Scott, R. T., Jr., Rechitsky, S., et al. (2026). Report of the PGDIS Task Group on the status of PGT-A. Reproductive BioMedicine Online, 52(6), Article 105498.
3. Wojciechowski, P., Kolonko, K., Giannopoulou, A., et al. (2026). Comparative Efficacy of Elinzanetant Versus Other Non-Hormonal Pharmaceutical Therapies for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Network Meta-Analysis. BJOG: An International Journal of Obstetrics & Gynaecology. Advance online publication.
4. Zhong, Y., Chang, C. L., Boumil, E., et al. (2026). Urinary Podocyte Enumeration: a Non -Invasive Assay for Early Prediction of Preeclampsia. Reproductive Sciences, 33(1, Suppl S), Abstract O-151.
5. Shulman, L. P., Sassarini, J., Proenca, C. C., et al. (2025). Findings from an indirect treatment comparison of non-hormonal pharmacological approaches for vasomotor symptoms: effects on sleep disturbances. Menopause: The Journal of The Menopause Society, 32(12), Abstract P-156.
6. Talaulikar, V., Shulman, L. P., Proenca, C. C., et al. (2025). Safety of non-hormonal treatments used for vasomotor symptoms: findings from a systematic literature review. Menopause: The Journal of The Menopause Society, 32(12), Abstract P-152.
7. Pabuccu, E., Aguilar, A., Antunes, R. d. A., et al. (2025). Why does the latest pharmacovigilance data not reflect clinical experience with dydrogesterone? Human Reproduction Open, 2025(3), Article hoaf030.
8. Kachko, V. A., Shulman, L. P., Kuznetsova, I. V., et al. (2024). Clinical Evaluation of Effectiveness and Safety of Combined Use of Dietary Supplements Amberen® and Smart B® in Women with Climacteric Syndrome in Perimenopause. Advances in Therapy, 41(8), 3183–3195.
9. Wyszynski, F. D., Demetriou, L., Renz, C., et al. (2024). Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry. Drug Safety, 47(9), 843–851.
10. Buckley, D. N., Lewinger, J. P., Gooden, G., et al. (2024). OvaPrintTM - a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer. Cancer Research, 84(5, Suppl 2), Abstract B040.
11. Katalinic, A., Noftz, M. R., Garcia-Velasco, J. A., et al. (2024). No additional risk of congenital anomalies after first-trimester dydrogesterone use: a systematic review and meta-analysis. Human Reproduction Open, 2024(1), Article hoae004.
12. Buckley, D. N., Lewinger, J. P., Gooden, G., et al. (2023). OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer. Clinical Cancer Research, 29(24), 5196–5206.
13. Wurst, K. E., Aliabadi, S., Wyszynski, D. F., et al. (2023). Characteristics of pregnant people treated with sotrovimab for COVID-19 from the COVID-19 international drug pregnancy registry (COVID-PR). Pharmacoepidemiology and Drug Safety, 32(Suppl 1), Abstract 464.
14. Ehrich, M., Sagaser, K. G., Porreco, R. P., et al. (2023). Capillary blood collection: exploring a new method to promote noninvasive prenatal screening access. American Journal of Obstetrics and Gynecology, 229(1), 75–76.
15. Buckley, D. N., Gooden, G., Shulman, L., et al. (2023). OvaPrint - a novel cfDNA methylation liquid biopsy for cancer risk assessment in high grade serous ovarian carcinoma. Cancer Research, 83(7, Suppl S), Abstract 1025.
16. Katalinic, A., Shulman, L. P., Strauss, J. F., et al. (2022). A critical appraisal of safety data on dydrogesterone for the support of early pregnancy: a scoping review and meta-analysis. Reproductive BioMedicine Online, 45(2), 365–373.
17. Treff, N. R., Savulescu, J., De Melo-Martín, I., et al. (2022). Should preimplantation genetic testing for polygenic disease be offered to all - or none? Fertility and Sterility, 117(6), 1162–1167.
18. Moisidis-Tesch, C. M., & Shulman, L. P. (2022). Iron Deficiency in Women's Health: New Insights into Diagnosis and Treatment. Advances in Therapy, 39(6), 2438–2451.
19. McQueen, D. B., Warren, C. M., Xiao, A. H., et al. (2021). Disparities among infertility patients regarding genetic carrier screening, sex selection, and gene editing. Journal of Assisted Reproduction and Genetics, 38(9), 2319–2325.
20. Wagner, A., Shulman, L., Lefler, T., et al. (2021). Provision of reproductive and cancer genetics services during COVID-19 pandemic. Molecular Genetics and Metabolism, 132(Suppl 1), Abstract eP552.

Profile Details
https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=16754
https://www.researchgate.net/scientific-contributions/Lee-P-Shulman-2146124834
https://scholar.google.com/citations?user=8kWrh6oAAAAJ&hl=en

WOS ResearcherID: DYV-3446-2022